SUBSCRIBE: Print / eNewsletter
Cancer Network presents exclusive coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Check out some of our topic specific ASCO coverage:
Nut Consumption Reduced Risk for Colon Cancer Recurrence, Death
Patients with stage III colon cancer who consumed at least two servings of nuts per week had significantly reduced risk for recurrence and death.
ACA Linked With Earlier Stage Cancer Diagnoses
The implementation of the Affordable Care Act, which increased insurance coverage, was associated with an increase in the diagnosis of several screenable cancers at an earlier stage.
Gefitinib Delayed Recurrence in Intermediate-Stage EGFR-Positive NSCLC
Adjuvant gefitinib significantly prolonged time to recurrence compared with the standard of care for patients with NSCLC with EGFR-activating mutations.
Upfront ASCT Still Best Option in Newly Diagnosed Multiple Myeloma
In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.
Binimetinib Improves PFS in NRAS-Mutated Metastatic Melanoma
The MEK inhibitor binimetinib resulted in improved progression-free survival and response rates vs dacarbazine in patients with NRAS-mutated metastatic melanoma.
Location of Primary Tumor Matters in Colorectal Cancer
A retrospective analysis of a phase III clinical trial found that the physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer.
Nivolumab/Ipilimumab Continues Improved Outcomes in Advanced Melanoma
A combination of the checkpoint inhibitors nivolumab and ipilimumab continues to demonstrate superior clinical activity vs ipilimumab monotherapy in treatment-naive patients with advanced melanoma.
ESPAC-4: Adjuvant Gemcitabine/Capecitabine in Resected Pancreatic Cancer
The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.
First-Line Atezolizumab Effective in Cisplatin-Ineligible Urothelial Cancer
Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.
Latest Immunotherapy Research in Treating Colorectal Cancer
In this interview we discuss the CheckMate 142 trial, which looked at nivolumab and ipilimumab for the treatment of metastatic colorectal cancer.